Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q2 FY22 results · Jul–Sep 2021
Panacea Biotec reported revenue from operations of ₹232.17 crore (up 27.6% from Q2 FY21) and net loss of ₹53.01 crore for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 232.17 | 182.02 | +27.6% | 132.45 | +75.3% |
| Other income | 2.03 | 2.00 | +1.5% | 3.23 | −37.2% |
| Total income | 234.20 | 184.02 | +27.3% | 135.68 | +72.6% |
| Profit before tax | (53.01) | (18.88) | Loss widened | (57.27) | Loss narrowed |
| Net profit for the period | (53.01) | (19.33) | Loss widened | (57.35) | Loss narrowed |
| EPS, basic (₹) | (8.65) | (3.16) | Loss widened | (9.36) | Loss narrowed |
| Net margin (%) | -22.8 | -10.6 | -43.3 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 119.26 | 118.20 | +0.9% | 36.26 | +228.9% |
| Other income | 3.47 | 2.95 | +17.6% | 4.15 | −16.4% |
| Total income | 122.73 | 121.15 | +1.3% | 40.41 | +203.7% |
| Profit before tax | (22.37) | 10.13 | Turned loss | (23.47) | Loss narrowed |
| Net profit for the period | (22.37) | 10.81 | Turned loss | (23.47) | Loss narrowed |
| EPS, basic (₹) | (3.65) | 1.76 | Turned loss | (3.83) | Loss narrowed |
| Net margin (%) | -18.8 | 9.1 | -64.7 |
Consolidated
- Filed with BSE
- 13 Nov 2021, 17:17 IST
- Board meeting
- 12 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Nov 2021, 17:17 IST
- Board meeting
- 12 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE